ADP-Ribosylation Inhibitor for Treatment of Cancer
The inhibitor has confirmed engagement in cells without toxic effects and have targeted therapeutic potential
Published: 29th June 2022

IP Status
- Patented
- Patent application submitted
Seeking
- Licensing
- Development partner
- Commercial partner